Patents Examined by Amanda L Aguirre
  • Patent number: 10836729
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: November 17, 2020
    Assignee: King Abdulaziz University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Patent number: 10815213
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Patent number: 10800744
    Abstract: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 13, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Patent number: 10787419
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 29, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Patent number: 10774028
    Abstract: A method for producing an asymmetric chain carbonate by reacting an alcohol with a halocarbonate ester compound in the presence of a basic magnesium salt.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Inventors: Tomohito Hamada, Michiaki Okada, Akiyoshi Yamauchi, Yosuke Kishikawa
  • Patent number: 10774042
    Abstract: The invention particularly relates to crystalline (solid) forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide), i.e. Form N, Form M, Form O and Form P. It also refers to a pharmaceutical composition or dosage form comprising said crystalline forms. The invention also concerns said pharmaceutical composition or dosage form for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said novel crystalline forms for the preparation of a pharmaceutical composition or dosage form.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: September 15, 2020
    Inventors: Monika Oracz, Piotr Garczarek, Przemyslaw Skoczen, Dominika Podwysocka, Marcin Szulc, Arkadiusz Majewski
  • Patent number: 10766855
    Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: September 8, 2020
    Inventors: Eduardo Munoz Blanco, Alberto Minassi, Maria Luz Bellido Cabello De Alba, Giovanni Appendino
  • Patent number: 10766867
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 10767054
    Abstract: Process for preparing disodium 5,5?-indigosulfonate, the feedstock being indigo, this process including the following steps: i) the indigo is subjected to a sulfonation treatment resulting in a mixture that contains 5,5?-indigosulfonic acid, this process including: ii) a reduction treatment is applied to the mixture obtained in step i), and optionally a purification step, so as to obtain a composition including leuco-5,5?-indigosulfonic acid, iii) the leuco-5,5?-indigosulfonic acid is isolated from the composition resulting from step ii), iv) the leuco-5,5?-indigosulfonic acid resulting from step iii) is oxidized to give disodium 5,5?-indigosulfonate.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 8, 2020
    Inventors: Babak Sayah, Stéphane Queru, Michel Feraud, Nicolas Lopez
  • Patent number: 10766865
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 8, 2020
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10759787
    Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: September 1, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Biao Lu, Xiaodong Shen, Mingxun He, Dong Liu, Minsheng Zhang
  • Patent number: 10752616
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 25, 2020
    Assignee: King's College London
    Inventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
  • Patent number: 10745349
    Abstract: The invention relates to ceramide dimers in which the amino alcohols are linked together by amide bonds via a dicarboxylic acid. The dicarboxylic acids have at least one sulfur atom in the chain. The invention also relates to a method for producing the ceramide dimers. The ceramide dimers are used as active ingredients to stabilize the skin barrier in cosmetic and pharmaceutical preparations.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 18, 2020
    Assignee: PATENTPORTFOLIO 2 S.À.R.L.
    Inventor: Stefan Sonnenberger
  • Patent number: 10745427
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, Minghong Zhong
  • Patent number: 10736885
    Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, peyronie's disease, dupuytren's contracture, or adhesive capsulitis.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: August 11, 2020
    Inventors: Diane Tang-Liu, Tiffany Liu
  • Patent number: 10738346
    Abstract: Fluorescence quenching nitrodiarylethene analogs are useful in oligonucleotide conjugates and probes. These analogs, whose absorption spectra are substantially blue-shifted relatively to emission spectra of common fluorophores (such as fluorescein), do not need to rely on spectral overlap of quencher absorbance and fluorophore's emission for their quenching abilities. The oligonucleotide-quencher conjugates may be used in detection methods for nucleic acid targets.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 11, 2020
    Assignee: ELITECHGROUP, INC.
    Inventors: Eugeny A. Lukhtanov, Noah Scarr
  • Patent number: 10738053
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: August 11, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • Patent number: 10730824
    Abstract: A method for producing an asymmetric chain carbonate by reacting an alcohol with a halocarbonate ester compound in the presence of a basic magnesium salt.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 4, 2020
    Inventors: Tomohito Hamada, Michiaki Okada, Akiyoshi Yamauchi, Yosuke Kishikawa
  • Patent number: 10723704
    Abstract: The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 28, 2020
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, Lisa Marie Frost, Frederick Arthur Brookfield, Stephen Martin Courtney, Carl Leslie North, Matthew Robert Conroy
  • Patent number: 10717754
    Abstract: Metal complexes such as those of formula (I) are contemplated by the present invention. The metal complexes may be used in catalytic reactions as a catalyst. The catalytic reaction may be an autotransfer process, for example hydrogen borrowing. Improved catalytic activity has been observed with certain metal complexes of the invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 21, 2020
    Assignee: University of Leeds
    Inventors: Stephen Philip Marsden, Patrick Columba McGowan, Roberta Lanaro, Andrew John Blacker